$1.40
+0.02 (+1.45%)
Open$1.40
Previous Close$1.38
Day High$1.46
Day Low$1.35
52W High$2.55
52W Low$0.56
Volume—
Avg Volume180.1K
Market Cap40.52M
P/E Ratio—
EPS$-3.59
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+787.1% upside
Current
$1.40
$1.40
Target
$12.42
$12.42
$7.12
$12.42 avg
$14.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 31.13M | 27.34M | 10.25M |
| Net Income | -107,551,611 | -84,998,638 | 2.27M |
| Profit Margin | -345.5% | -328.2% | 22.1% |
| EBITDA | -83,723,296 | -69,842,932 | 3.06M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | +13.9% | +13.9% | +24.9% |
| Debt/Equity | 4.75 | 4.75 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |